Search
Scientists Found a Hidden Immune Organ Inside the Human Skull — What It Means for Brain Cancer Treatment and Regulatory Affairs
Scientists at Washington University School of Medicine in St. Louis have identified a **skull immune organ** — lymphoid structures inside the skull's bone marrow that act as first responders to brain disease. Published in *Nature* on 19 August 2026, the study shows microscopic channels carry antigens from the brain into skull marrow, where **T follicular helper cells** train **B cells** to fight threats, including glioblastoma, before distant lymph nodes react. Similar cells
Aug 2812 min read
FDA's Streamlined Nonclinical Safety Guidance for Monoclonal Antibodies: What It Means for Regulatory Affairs Professionals in 2026
In December 2025, the US Food and Drug Administration (FDA) published draft guidance — "Monoclonal Antibodies: Streamlined Nonclinical Safety Studies" (Docket FDA-2025-D-4634) — recommending that sponsors of monospecific monoclonal antibodies (mAbs) can reduce or eliminate long-duration animal toxicology studies, including in nonhuman primates (NHPs), where a robust weight-of-evidence (WoE) risk assessment supports doing so. It affects any company developing single-target mAb
Aug 2511 min read
FDA's August 2026 PDUFA Wave: Five Landmark Decisions Regulatory Affairs Professionals Need to Know
The FDA PDUFA dates for August 2026 mark one of the busiest single-month regulatory windows of the year, with five separate Prescription Drug User Fee Act (PDUFA) decisions due between 5 and 28 August. The decisions affect a new mRNA influenza vaccine, an oral multiple myeloma therapy, a single-tablet HIV regimen, a radiopharmaceutical for neuroendocrine tumours, and a first-in-class treatment for an ultra-rare bone disorder. Sponsors include Moderna, Bristol Myers Squibb, Gi
Aug 712 min read
EMA OPEN Framework 2026 Update: What Pharma and Regulatory Affairs Teams Need to Know
The EMA OPEN framework (Opening Procedures at EMA to Non-EU Authorities) allows the European Medicines Agency (EMA) to run near-concurrent scientific assessments of certain medicines alongside seven non-EU regulatory partners, while each authority keeps full independence over its own decision. Originally piloted for COVID-19 medicines in December 2020, it was expanded to a wider range of therapeutic areas on 20 July 2023 and remains the operational basis for cross-border coll
Aug 511 min read
GSK's £400m Cambridge Global Centre of Excellence: What the Investment Means for UK Life Sciences and Regulatory Affairs Careers
GSK's £400 million Cambridge investment will fund a new flagship research and development centre on the Cambridge Biomedical Campus, housing more than 1,000 scientists and replacing GSK's long-standing Stevenage site by 2029. Announced on 28 July 2026, the move forms part of a wider £1.9 billion cost-savings programme and is framed by the UK government as evidence that its Modern Industrial Strategy is attracting investment into life sciences. For regulatory affairs professio
Jul 3112 min read